Imexpharm honored as the best company in annual reports and company management

This is the result of the annual Voting for Listed Enterprises, organized by the Ho Chi Minh City Stock Exchange, Hanoi Stock Exchange, Dragon Capital, and Investment Newspaper. This voting aims to honor companies that have demonstrated good corporate governance and management practices through the internal disclosure of information and communication channels with market regulatory agencies.

The Organizing Committee's assessment shows that the Annual Reports and Corporate Governance awarded can also be seen as a typical model that businesses on the market can refer to. In addition, this is also the basis for policy makers and state management agencies to improve general and detailed standards to effectively manage and operate businesses, sectors, and industries, building national competitiveness.

This is a proud result that recognizes Imexpharm's efforts to become a listed company with professional, transparent operations that always comply with and meet international standards and practices in financial reporting, auditing, and corporate governance.

The results of the Listed Enterprises Voting were announced on December 15 in Cam Ranh, Khanh Hoa, to evaluate and encourage listed companies to improve the professionalism, transparency, and ability to convey information of their annual reports, financial reports, and sustainable development reports, and to increase the ability of investors to access information about listed companies. In addition, this activity also helps to assess the implementation of corporate governance of listed companies based on reliable information that companies publicly disclose to regulators and investors, and encourages the application of international standards and practices on corporate governance.

According to the Organizing Committee, this year, a total of 116 annual reports were evaluated, of which 24 reports came from the financial sector and 92 reports came from the non-financial sector.

General Director of Imexpharm, People's Doctor, Pharmacist Tran Thi Dao, shared: "As a pharmaceutical company that was listed on the stock exchange as early as 2006, we pursue the goal of becoming a sustainable, professional, and transparent company in all activities, especially in governance activities. This result is a positive recognition of Imexpharm's efforts and increases the trust of customers, shareholders, and investors in Imexpharm over the past time."

"Towards the goal of sustainable development, Imexpharm always invests deeply in product quality while ensuring reasonable prices for patients. Quality is one of the outstanding points of Imexpharm that has been recognized by hospitals, doctors, and patients in recent years. To do this, we always maintain an international standard production system, focus resources, and invest systematically in manufacturing plants that meet EU-GMP and other advanced international standards," General Director Tran Thi Dao shared further.

Looking back at the first 11 months of the year, Imexpharm has made strong strides in its business operations in the context of the domestic economy still facing many difficulties after two years of Covid-19. Accordingly, Imexpharm's total revenue in November this year reached VND 230.3 billion, up 11.9% from November 2022. In the first 11 months of 2023, Imexpharm achieved net revenue of VND 1.788.8 billion and pre-tax profit of VND 360.6 billion; up 23.2% and 36.2%, respectively, compared to the same period in 2022.

With this result, Imexpharm has achieved 102.2% of its revenue plan (over 2.2% of the planned revenue) and 103% of its profit target (over 3% of the planned profit) according to the plan proposed by the 2023 Annual General Meeting of Shareholders. This is an impressive business result and a testament to the sustainable and efficient growth of Imexpharm.

To continue this growth, Imexpharm will focus on effectively controlling strategic goals using the BSC (Balanced Scorecard) tool for each block and accelerating the progress of completing the 2023 plan proposed by the Annual General Meeting of Shareholders. In addition, the Company will closely monitor the production plan at factories to ensure that it meets the demand for market items during the end of the year. At the same time, IMP will also closely control and manage inventory, ensuring the effectiveness of the reserve plan at a safe level for both finished products and production materials to meet business plans and market needs. Along with that, Imexpharm will review the financial plan, including the budget and cash flow, to ensure that the Company has sufficient resources to maintain stable operations in the last quarter and the following year.